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A B S T R A C T
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract.
When making treatment plan it is very important to make proper tumor aggressiveness estimation. Traditionally, the
best prognostic factors are tumor size and number of mitoses. The aim of this study was to define which GIST classifica-
tion (Amin’s or Newman’s classification or Fletcher’s Consensus Criteria) is the most significant determining prognosis
and has the strongest impact on survival. This study included 63 GIST patients whose tumor specimens were evaluated
by standard histopathological methods and classified based on histological assessment of malignant behavior to the
three different systems. Comparison of those classification systems was done and none of them was proven to be statisti-
cally significantly better in predicting overall survival and probability of lethal outcome. We conclude that all three clas-
sifications are comparable in prediction of malignant behavior. The worst prognostic factor is existence of metastases at
the time of disease diagnosis.
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Introduction
Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal neoplasms of the gastrointestinal
tract. They can evolve in any part of gastrointestinal sys-
tem, especially in the stomach and small intestine, but
can also originate in the mesentery and omentum. They
are very rare (0.1–1% of all malignant gastrointestinal
system tumors)1–7.
The most critical development which distinguished
GISTs as a unique clinical entity was the discovery of
c-Kit proto-oncogene mutations8. More than 90% of ma-
lignant GISTs have aberrant signal transmission medi-
ated by KIT9,10.
Immunohystochemical characteristics of GISTs are
the following: almost all are KIT (CD 117) positive,
60–70% are CD 34 positive, 30–40% are SMA positive,
they are very rarely desmin positive and 5% are S-100
positive10–12.
GISTs usually develop in patients older than 50
years13. The average age is between 55 and 65 years.
Some clinical studies have shown that these tumors oc-
cur more often in men, while other studies have shown
similar distribution between men and women14–28.
When decision about GIST treatment is made, assess-
ment of it’s biological behavior has to be included. Expe-
rientially, the best prognostic factors are tumor size and
the number of mitoses. Although, there are some tumors
which are big in size and have benign course and also
some very small tumors which are extremely aggressive
and have markedly malignant course. Tumor size by it-
self is not indisputable prognostic factor, but in combina-
tion with other prognostic factors it’s meaning becomes
important7.
Over many years, there were discussions and analyses
what are criteria for distinction of benign and malignant
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GISTs or at least for detection of lesions which are more
likely to metastasize29–34. It is still unresolved which are
the breaking points suggesting malignant behavior. Fac-
tors like mucous invasion, tumor necrosis and high cellu-
larity were shown to be statistically significant but were
not reproducible and were not useful in individual cases.
Almost every GIST which causes clinical symptoms or
signs requiring therapy has potentially malignant behav-
ior.
The most common place of relapse is abdominal cav-
ity or appearance of hepatic metastases what then im-
plies poor prognosis.
Amin wanted to divide GISTs considering their bio-
logical behavior into three categories according to the
histology: 1) Benign – less than 5 mitoses / 50 HPF (High
Power Field), tumor size less than 5 cm; 2) Borderline –
less than 5 mitoses / 50 HPF, tumor size more than 5 cm;
3) Malignant – more than 5 mitoses / 50 HPF, any tumor
size.
According to histological criteria Newman and associ-
ates had similar attempt of GISTs graduation: 1) Benign
– 0–2 mitoses per 30 HPF / spindle-cell type without
atypia or 0 mitoses per 30 HPF / spindle-cell type; 2) Bor-
derline – 2–3 mitoses per 30 HPF / spindle-cell type, mild
polymorphism and hyperchromasia or 3–4 mitoses per 30
HPF / spindle-cell type without atypia or 1 mitose per 30
HPF / epitheloid type lesion; 3) Malignant – more than 5
mitoses per 30 HPF / spindle-cell type without atypia or
more than 3 mitoses per 30 HPF / spindle-cell type, poly-
morphism and hyperchromasia or more than 2 mitoses
per 30 HPF / epitheloid type lesion.
Furthermore, most of the researchers assume it
better to categorize lesions according to aggressive be-
havior risk – a task that is currently still hard to do cor-
rectly. The group of authors had idea to develop a scheme
based on risk assessment35. For the specific case of GIST,
risk of aggressive behavior is estimated as either very
low, low, intermediate or high. Hopefully, only small pro-
portion of cases (less than 10%) will take an unexpected
clinical course, although none of the lesions can be pro-
claimed benign.
Group of authors, have collected their experiences
and opinions and have defined aggressive behavior risk
of GISTs as follows: 1) Very low risk: – size* less than 2
cm, number of mitoses** less than 5 mitoses per 50 HPF;
2) Low risk: – size* 2–5 cm, number of mitoses** more
than 5 mitoses per 50 HPF; 3) Intermediate risk: – size*
less than 5 cm, number of mitoses** 6–10 mitoses per 50
HPF or size* 5–10 cm, number of mitoses** less than 5
mitoses per 50 HPF; 4) High risk: – size* more than 5 cm,
number of mitoses** more than 5 mitoses per 50 HPF or
size* more than 10 cm, any number of mitoses** or any
size, number of mitoses** more than 10 mitoses per 50
HPF
These criteria are called NIH (National Institute of
Health) Consensus Criteria.
Patients with metastatic GISTs are candidates for
imatinib mesylate (tyrosine kinase receptor inhibitor)
therapy from which clinical results are very good and en-
couraging. Imatinib mesylate is also part of adjuvant
therapy in patients with resected high or intermediate
risk GISTs and can be part of therapy prior to surgery in
patients with unresectable disease36–43.
Aim
The aim of this study was to define which criteria are
of prognostic importance and applicable in clinical
praxis.
Amin’s and Newman’s classification and NIH Con-
sensus Criteria are compared in order to define which of
them is prognostically most significant and which one
has the strongest impact on survival. This comparison,
based on obtained results, could suggest which classifica-
tion is the most useful one in the routine clinical praxis.
The hypothesis was that NIH Consensus Criteria de-
scribed by Fletcher and associates were the most useful
for determining GIST prognosis as they are the most fre-
quently used and described in the literature. The aim of
the study was also to clearly show how existence of
metastases at the time of diagnosis affects overall sur-
vival.
Patients, Material and Methods
Here presented study included 63 GIST patients diag-
nosed and surgically treated at University Hospital for
Tumors in Zagreb, Croatia, from 01.01.1995 until 31.12.
2012. Available data on patients, their tumors and ap-
plied therapies were collected together with their sur-
vival length.
Distribution of the patients according to the gender,
age, tumor size and number of mitoses was analyzed. Pa-
tients were also distributed according to the tumor loca-
tion within gastrointestinal system and tumor cells mor-
phology defined as spindle-cell type, epitheloid type or
mixed lesion type. An overview of immunohistochemical
profile of the evaluated GISTs was done.
Tumor specimens were retrospectively analyzed after
clinical diagnosis was established and surgery was per-
formed. Histopathological analysis and immunohistoche-
mical diagnosis of GISTs were established.
The tumor specimens, obtained by surgery, were pre-
pared for histopathological analysis by standard routine
method consisting of fixation in 10% buffered formalin.
Afterwards, tumor tissue was embedded in the paraffin
blocks, sectioned at 3 to 5 microns and stained by hema-
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* size presents only one dimension of tumor, the biggest diameter can depend on pre- and postfixation, although in small bowel lesions aggressive behav-
ior risk threshold is 1 to 2 cm smaller than in the lesions situated on other localization
** number of mitoses is subjective category based on different identification of mitoses, size of all examined high power fields can be different
toxylin and eosion. The stained tumors sections were
than examined by light microscope.
For immunohistochemical analysis eight additional
sections were done. Immunohistochemical method using
PAP complex (peroxidase-antiperoxidase complex) and
ABC (avidin-biotin complex) / HRP (horse-radish peroxi-
dase) DAKO NoK0355 was applied. PAP complex con-
sists of antigen, peroxidase and peroxidase antibody. The
standard procedure for immunohistochemical staining
was used. In all tumor specimens expression of the CD
117, CD 34, vimentin, SMA, S-100, MAGE A1, MAGE
A3/4 and NY ESO 1 was evaluated.
In order to determine biological behavior of the tu-
mors, they can be classified according to the criteria of
Amin and associates44 and Newman and associates45 as
malignant, borderline or benign. Taking into account the
fact that small tumor lesions (even smaller than 2 cm in
diameter) and lesions with minimal number of mitoses
can also metastasize, most of the authors consider that it
is better to divide GISTs in groups according to risk of
aggressive behavior. According to the National Institute
of Health Consensus Criteria, GISTs should be divided
into four groups: very low risk, low risk, intermediate
risk, and very high risk of aggressive behavior7.
Based on routine classical histopathological examina-
tion, morphology of the tumor cells was examined. The
tumors were divided into three groups depending on cell
features. They were characterized as spindle-cell lesions,
epitheloid or mixed lesions (this is part of Newman clas-
sification).
All the collected GISTs were also examined immuno-
histochemically. Results of immunohistochemical stain-
ing were shown with semiquantitative method as fol-
lows:
¿ negative reaction (–) : there is no tumor cell stain-
ing
¿ weekly positive reaction (+): less than 10% of tu-
mor cells are stained positively
¿ moderately positive reaction (++): 11–50% of tu-
mor cells are stained positively
¿ extremely positive reaction (+++): more than 50%
of tumor cells are stained positively.
As positive expression were considered moderately
positive, extremely positive and weekly positive reaction
whereas negative expression was considered negative re-
action.
Statistics
The obtained data were statistically analyzed by in-
terrogating differences and correlations using SSPS 17
(IBM, Somers, New York) and MedCalc Software 12.2.1
(Mariakerke, Belgium). Normal distribution of continu-
ous variable was considered reduced and rounded distri-
bution less than 1. Regularity of distribution was checked
by Smirnov-Kolmogorov test. Nominal indicators were
shown by prevalence distribution considering groups and
participation. In order to establish differences between
two independent samples, student T test was employed.
Mann-Whitney test was used for determining differences
between two independent samples which show irregular
distribution. For defining differences between propor-
tions of two independent samples c2-test was used and
for defining differences between proportions of more
than two independent samples Pearson c2-test was used.
Kendall tau b test was employed for determining correla-
tion between samples for nonparametric analysis. Influ-
ence of covariance group on overall survival was investi-
gated by Cox regression analysis and influence of indi-
vidual variable on overall survival was investigated by
Kaplan-Meier model. Statistical relevance was accepted
for p<0.05.
Results
The overall number of 63 patients with clinically and
pathologically diagnosed GISTs since 01.01.1995 until
31.12.2011 at the University Hospital for Tumors, Zag-
reb, Croatia was included in this study.
Of all patients, 31 (49.2%) were men and 32 (50.8%)
were women. The average age of all patients was 58,7
years (median 62, min 16, max 80), the average age of all
male patients was 59.4 years (median 61, min 18, max
79) and the average age of all female patients was 57.9
years (median 63, min 16, max 80), without statistically
significant difference between genders (p=0.700).
The average overall survival for all patients was 74.5
months (median 71, min 1, max 176), the average overall
survival for female patients was 70.01±53.46 months
(median 87 months) and for male patients was 78.25±
47.44 months (median 61 months), but without statisti-
cally significant difference between genders (p=0.551).
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TABLE 1
DISTRIBUTION OF THE GISTS BASED ON PRIMARY TUMOR
LOCALIZATION IN THE GASTROINTESTINAL SYSTEM AND
IMMUNOHISTOCHEMICAL EXPRESSION OF THE CD 117, CD 34,
VIMENTIN, SMA, S100, MAGE A1, MAGE A/4, NY ESO
Tumor localization Number of cases
Oesophagus 1 (1.6%)
Stomach 39 (61.9%)
Small intestine 13 (20.6%)








CD 117 63 (100%) 0 (0%)
CD 34 50 (79.4%) 13 (20.6%)
Vimentin 63 (100%) 0 (0%)
SMA 39 (61.9%) 24 (38.1%)
S-100 24 (37.1%) 39 (61.9%)
MAGE A1 22 (34.9%) 41 (65.1%)
MAGE A3/4 4 (6.3%) 59 (93.7%)
NY ESO– 1 7 (11.1%) 56 (88.9%)
The average tumor size of all collected cases was 6.0
cm (median 5.0, min 0.9, max 25).
Detailed description of the tumors was given consid-
ering different tumors’ characteristics (Table 1). Accord-
ing to the localization of the primary GISTs, patient were
distributed into five groups. All the tumor specimens
were immunohistochemically assessed and the expres-
sion of the CD 117, CD 34, vimentin, SMA, S-100, MAGE
A1, MAGE A3/4 and NY ESO was determined. The re-
sults of the immunohistochemical staining was deter-
mined by usage of semiquatitative method.
In all GIST cases, histopathological examination de-
fined number of mitoses, tumor size and morphology of
the tumor cells. Considering two parameters (tumors
size and number of mitoses) patients were first classified
into three groups according to Amin’s classification (Ta-
ble 2).
Afterwards, all those GISTs were divided into three
groups according to Newman’s classification considering
number of mitoses and tumor cell morphology (Table 3).
All the tumor cases were also classified considering
number of mitoses and tumor size into four groups ac-
cording to National Institute of Health Consensus Crite-
ria (Table 4).
There was statistically significant positive correlation
between grades of Amin’s, Newman’s and Fletcher’s
NIH classification and probability of patients’ death. In
other words, the higher group tumor belonged to (malig-
nant tumors in Amin’s and Newman’s classification and
intermediate and high risk tumors in Fletcher’s classifi-
cation) the probability of death as outcome was more
likely (Table 5).
There was statistically significant positive correlation
between classification groups within Amin’s, Newman’s
and NIH Consensus Criteria classifications and overall
survival. In other words, patients with benign or low risk
tumors had statistically significantly longer overall sur-
vival then those with more aggressive forms of tumors
(see Table 6).
Distribution of the GIST patients considering exten-
sion of disease and overall survival expressed in months
was also shown (Table 7).
According to Kaplan-Meier analysis of survival, pa-
tients having metastases at the time of diagnosis lived
statistically significantly shorter (p<0.001) (Figure 1)
There was statistically significant correlation be-
tween existence of metastases at the time of diagnosis
and probability of lethal outcome (r=0.541; p<0.001).
Logistic binary regression considering influence of ex-
istence of metastases at the time of disease diagnosis on
possibility of patients’ death was done. The patient who
had metastatic disease at the time of diagnosis had 16
times more chances to die then the patients who had no
metastases at the time of disease diagnosis (p<0.001).
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TABLE 2
AMIN’S CLASSIFICATION OF THE GISTS, OVERVIEW OF






Lethal outcome Overall sur-
vival median
in monthsYes No
Benign 24 (38.1%) 3 (4.8%) 21 (33.3%) 87
Borderline 18 (28.6%) 2 (3.2%) 16 (25.4%) 120
Malignant 21 (33.3%) 9 (14.3%) 12 (19.0%) 29
TABLE 3
NEWMAN’S CLASSIFICATION OF THE GISTS, OVERVIEW OF






Lethal outcome Overall sur-
vival median
in monthsYes No
Benign 25 (39.7%) 2 (3.2%) 23 (36.5%) 97
Borderline 17 (27.0%) 4 (6.3%) 13 (20.6%) 68
Malignant 21 (33.3%) 8 (12.7%) 13 (20.6%) 29
TABLE 4
NIH CONSENSUS CRITERIA CLASSIFICATION OF THE GISTS,
OVERVIEW OF PATIENTS WHO DIED AND OVERALL SURVIVAL
MEDIAN EXPRESSED IN MONTHS









3 (4.8%) 0 (0%) 3 (4.8%) 36
Low risk 22 (34.9%) 3 (4.8%) 19 (30.2%) 95
Interme-
diate risk
17 (27.0%) 2 (3.2%) 15 (23.8%) 94
High risk 21 (33.3%) 9 (14.3%) 12 (19.0%) 29
TABLE 5




















ROC curve showed sensitivity and specificity of test
or sensitivity and specificity of metastases existence at
the time of diagnosis on probability of lethal outcome
(Figure 2).
Sensitivity of metastases existence at the time of diag-
nosis for predicting patient’s death was 64.3% (95% IP
35.1–87.2), whereas specificity was 89.80% (95% IP 77.8–
96.6).
When comparing three classifications (Amin’s, New-
man’s and Fletcher’s NIH classification system) and
their influence on overall patients’ survival no statisti-
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TABLE 6
OVERALL SURVIVAL OF THE PATIENTS CATEGORIZED ACCORDING TO THE THREE CLASSIFICATION SYSTEMS
Overall survival (months) Statistics
Median 25. P. 75. P. Z p (post hoc)
Amin’s
classification






Borderline (B) 120 68 140
Malignant (C) 29 15 68
Newman’s
classification






Borderline (B) 68 30 93
Malignant (C) 29 18 100
NIH risk









Low (B) 95 56 115
Intermediate (C) 94 39 135
High (D) 29 18 75
TABLE 7
DISTRIBUTION OF THE GIST PATIENTS CONSIDERING











37 (77.08%) 5 (7.9%) 44 (69.8%) 92
Metastatic
disease
11 (22.92%) 9 (14.3%) 5 (7.9%) 35
Fig. 1. Overall survival of patients with and without metastases
at the time of GIST diagnosis. Kaplan Meier survival analysis.
Fig. 2. Sensitivity and specificity of metastases existence at the
time of GIST diagnosis in predicting lethal outcome.
cally significant difference between three groups was
found (Figure 3, Table 8). So the primary hypothesis
which considered Fletcher’s NIH classification the most
powerful in predicting prognosis of patients with GISTs
is not sustainable.
Discussion and Conclusions
Considering gender distribution there was no statisti-
cally significant difference. Of altogether number of 63
patients, 49.2% (31/63) were men and 50.8% (32/63) were
women. When reviewing world literature slightly more
males are diagnosed with GISTs than females, although
many reviews have reported no sex predilection what
corresponds to finding of conducted study46–49.
GISTs are most commonly diagnosed in the second
half of the sixth and the first half of the seventh decades
of life (ie, 55–65 y)47,48. Rarely GISTs are discovered in
younger adults.
The average age of all patients in our study was 58.7
years, the average age of all male patients was 59,4 years
and the average age of all female patients was 57.9 years,
without statistically significant difference between gen-
ders (p=0.700). So our data are completely in concor-
dance with literature findings.
The average overall survival of all patients in our
study was 74.5 months, the average overall survival of fe-
male patients was 70.01 months and of male patients was
78.25 months. There was no statistically significant dif-
ference in overall survival between genders (p=0.551)
what is in concordance with some references48,49. Litera-
ture review shows that in some studies male sex is in pos-
itive correlation with statistically significantly worse
prognosis50–54.
According to the literature, GISTs distribution is as
follows: the most often they occur in stomach (50–60%),
small intestine (20–30%)30,31, large intestine and rectum
(10%), in esophagus they occur rarely in 5% of cases and
in 5% they are placed elsewhere in abdominal cavity. Spo-
radically omentum, mesenterium and retroperitoneum
can be revealed as primary site of disease18–28.
The most common localization of the GIST in our
study was stomach (61.9%), followed by small (20.6%)
and large intestine (11.1%), what is also observed in
some other studies46,48,49. In many studies it was ob-
served that non-gastric localization of the primary GISTs
has had statistically significant negative influence on
survival48–53.
This study comprised altogether number of 63 GIST
cases. When analyzing immunohistochemical character-
istics, all of those cases were CD 117 and vimentin posi-
tive. SMA was positive in 61.9% (39/63) and negative in
38.1% (24/63), S-100 was positive in 38.1% (24/63) and
negative in 61.9% (39/63), further 50/63 (79.4%) cases
were CD 34 positive while 13/63 (20.6%) were CD 34 neg-
ative. In Cao’s Study (2010) positive rate for the KIT pro-
tein (CD 117) in immunostaining was 94.5% (171/181),
while that for CD34 was 86.2% (156/181). In 2003., Lin in
his study found that CD117 was positive in 89% (81/91)
tissue samples, there were also 72.8% (59/91) cases posi-
tive for CD34, 16% (13/91) positive for SMA and 14.8%
(12/91) positive for S10055. In Perez’s study CD 117 was
positive in 71% (25/35), CD 34 in 54% (19/35) and S100
was positive in 37% (13/35)56. S100 positivity in Perez’s
study is comparable to our results.
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TABLE 8
COMPARISON BETWEEN AMIN’S CLASSIFICATION, NEWMAN’S
CLASSIFICATION AND NIH RISK AUC (AREA UNDER CURVE)
Amin’s classification ~ Newman’s classification
Difference between areas 0.007
Standard error 0.040
95% confidence interval –0.071 do 0.085
z value 0.165
Statistical significance p=0.869
Amin classification ~ NIH risk
Difference between areas 0.010
Standard error 0.033
95% confidence interval –0.054 do 0.074
z value 0.312
Statistical significance p=0.755
Newman classification ~ NIH risk
Difference between areas 0.004
Standard error 0.041
95% confidence interval –0.076 do 0.083
z value 0.090
Statistic significance p=0.929
Fig. 3. Sensitivity and specificity of three classifications in pre-
dicting lethal outcome.
The expression of CD 117 is important because tar-
geted therapy such as imatinib mesylate, a KIT tyrosine
kinase inhibitor, may play an important role in the treat-
ment of GIST48.
All three classification systems showed statistically
significant positive correlation between grades of Amin’s,
Newman’s and Fletcher’s NIH classification and proba-
bility of patients’ death. In patients whose tumors be-
longed to more aggressive groups (malignant tumors in
Amin’s and Newman’s classification and intermediate
and high risk tumors in Fletcher’s classification) lethal
outcome was more probable and when overall survival of
patients belonging to different groups was compared,
statistically significant difference was observed (overall
survival of patients belonging to more aggressive groups
was shorter).
In our study, we did not found statistically significant
difference between three different classification systems
(Amin’s, Newman’s and Fletcher’s NIH classification
system) in predicting prognosis and overall survival of
the patients. None of those systems predicted poor prog-
nosis better than the other.
In 2007 introduction of adjuvant imatinib mesylate in
GISTs’ therapy raised debate over the accuracy of NIH
risk criteria. In univariate analysis, high or intermediate
risk group, mitotic index>5/50 HPF, primary tumor size
<5 cm, non-gastric primary localization, male sex, R1 re-
section, tumor rupture and epitheloid cell or mixed cell
pathological subtype negatively influenced disease free
survival51. Many authors found that NIH categorization
is simple and effective to evaluate GIST behavior and
prognosis48,49.
Korean author Cho found that GIST classification
based on original tumor location, size and mitosis is more
efficient than the NIH criteria in predicting patients’
survival, but the mechanism still needs to be clarified52.
Probably some sort of modification of some of these
systems could be helpful in predicting prognosis and de-
ciding which tumors should be treated with adjuvant
therapy.
Rutkowski and associates studied influence of a new
modification of the NIH Consensus Criteria (the Jonescu
risk criteria), NCCN-AFIP and several clinical and pa-
thological factors, including tumor rupture on relapse
free survival (RFS) in prospectively collected tumor reg-
istry series consisting of 640 CD 117 positive GIST cases.
In univariate analyses, high Jonescu risk group, tumor
mitotic count>5/50HPF, tumor size>5 cm, non-gastric
localization, tumor rupture and male were independent
poor prognostic factors. Jonescu criteria, which include
four prognostic factors (tumor size, site, mitotic count
and rupture), were found to be reliable tool for assessing
prognosis of operable GISTs. Jonescu criteria can iden-
tify particularly well high risk patients who are likely to
be proper candidates for adjuvant therapy52.
In our study, metastases at the time of diagnosis were
significantly positively correlated with death as patients’
possible outcome. The similar finding had Bertin in 2007
who found that patients with metastases at laparotomy
have significantly lower 5-year survival rate55.
We conclude the following: when comparing three
classifications (Amin’s, Newman’s and NIH) based on
histological assessments of malignant behavior of GISTs,
neither one classification is better in prediction of overall
survival than the other.
We can also conclude that the most negative prognos-
tic factor is the existence of metastases at the time of dis-
ease diagnosis.
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KLASIFIKACIJE GIST-OVA U PREDVI\ANJU AGRESIVNOG PONA[ANJA:
ISKUSTVO JEDNE USTANOVE
S A @ E T A K
Gastrointestinalni stromalni tumori (GIST-ovi) su naj~e{}e mezenhimalne neoplazme probavnog sustava. Pri dono-
{enju odluke o planu lije~enja vrlo je va`no dobro procijeniti agresivnost tumora. Tradicionalno, najbolji prognosti~ki
~imbenici su veli~ina tumora i broj mitoza. Cilj provedenog istra`ivanja bio je definirati koja klasifikacija GIST-ova
(Aminova, Newmanova ili Fletcherova klasifikacija) je najzna~ajnija u predvi|anju prognoze i ima najve}i utjecaj na
pre`ivljenje. Provedeno istra`ivanje obuhvatilo je 63 bolesnika s GIST-om ~iji su uzorci tumora bili evaluirani stan-
dardnim patohistolo{kim metodama i klasificirani na temelju histolo{ke procjene malignosti u tri razli~ita sustava.
Provedena je usporedba spomenutih klasifikacijskih sustava i niti jedan se nije pokazao statisti~ki zna~ajno boljim u
predvi|anju duljine pre`ivljenja i vjerojatnosti smrtnog ishoda. Zaklju~no, sve tri klasifikacije podjednako dobro pred-
vi|aju maligno pona{anje tumora. Najlo{iji prognosti~ki ~imbenik je postojanje metastaza u trenutku postavljanja di-
jagnoze osnovne bolesti.
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